Results of Annual General Meeting

Arix Bioscience PLC (ARIX) Results of Annual General Meeting 14-Jun-2021 / 14:55 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience Plc Results of Annual General Meeting LONDON, 14 June 2021: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that its Annual General Meeting (the "Meeting") was held today, Monday, 14 June 2021, at 14.00 BST. At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 18 May 2021 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 10 were passed as ordinary resolutions. Resolutions 11 to 14 were passed as special resolutions. Full details of the poll results are set out below and will also be available on the Company's website. No RESOLUTION VOTES FOR % VOTES AGAINST % TOTAL VOTES % of ISC VOTED VOTES WITHHELD 1 To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2020 61,517,202 92.76% 4,800,657 7.24% 66,317,859 50.32 2,783 2 To approve the Directors' Remuneration Report 58,196,535 92.34% 4,825,953 7.66% 63,022,488 47.82 3,298,154 3 To re-elect Giles Kerr as a Director 61,344,286 92.51% 4,964,902 7.49% 66,309,188 50.31 11,454 4 To elect Peregrine Moncreiffe as a Director 60,271,773 92.55% 4,855,144 7.45% 65,126,917 49.42 1,193,725 5 To elect Maureen O'Connell as a Director 58,841,750 90.36% 6,274,013 9.64% 65,115,763 49.41 1,204,879 6 To elect Isaac Kohlberg as a Director 58,842,050 90.35% 6,285,167 9.65% 65,127,217 49.42 1,193,425 7 To elect Robert Lyne as a Director 60,072,787 90.59% 6,236,701 9.41% 66,309,488 50.31 11,154 8 To appoint BDO LLP as auditors of the Company 61,500,167 92.74% 4,817,701 7.26% 66,317,868 50.32 2,774 9 To authorise the Audit and Risk Committee of the Company to fix the remuneration of the auditors 61,516,153 92.76% 4,804,189 7.24% 66,320,342 50.32 300 10 To authorise the Directors to allot shares 61,019,094 92.01% 5,297,239 7.99% 66,316,333 50.32 4,309 11 Authority to disapply statutory pre‐ emption rights* 59,364,402 89.52% 6,951,931 10.48% 66,316,333 50.32 4,309 12 Additional authority to disapply statutory pre‐ emption rights* 59,363,555 89.52% 6,952,778 10.48% 66,316,333 50.32 4,309 13 To authorise the Company to purchase its own shares* 61,478,596 92.71% 4,836,857 7.29% 66,315,453 50.32 5,189 14 Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice* 61,517,295 92.76% 4,803,047 7.24% 66,320,342 50.32 300 *Special resolutions In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 18 May 2021, which is available on Arix investor relations website. A replay of the presentation and the Meeting will be available via webcast shortly after the event on the Company's investor relations website at: https://arixbioscience.com/investor-relations/events-presentations [ENDS] For more information on Arix, please contact: Arix Bioscience plc Charlotte Parry, Head of Investor Relations [phone] [e-mail] Optimum Strategic Communications Mary Clark, Supriya Mathur, Shabnam Bashir [phone] [e-mail] About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

ISIN:	GB00BD045071
Category Code:	RAG
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	111187
EQS News ID:	1207766

End of Announcement	EQS News Service